Muhandiramge J., Warner E.T., Zalcberg J.R., Haydon A., Polekhina G., van Londen G.J. et al. Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS). Cancers. 2023;15(4):1017. https://doi.org/10.3390/cancers15041017..
DOI: 10.3390/cancers15041017
DeVita V.T., Chu E. A History of Cancer Chemotherapy. Cancer Res. 2008;68(21):8643–8653. https://doi.org/10.1158/0008-5472.CAN-07-6611..
DOI: 10.1158/0008-5472.CAN-07-6611
Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018;26(S1):5–9. https://doi.org/10.1007/s00520-018-4131-3..
DOI: 10.1007/s00520-018-4131-3
Владимирова Л.Ю., Гладков О.А., Королева И.А., Румянцев А.А., Семиглазова Т.Ю., Трякин А.А. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Злокачественные опухоли. 2022;12(3s2-2):26–39. https://doi.org/10.18027/2224-5057-2022-12-3s2-26-39..
DOI: 10.18027/2224-5057-2022-12-3s2-26-39
Hesketh P.J., Kris M.G., Grunberg S.M., Beck T., Hainsworth J.D., Harker G. et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15(1):103–109. https://doi.org/10.1200/JCO.1997.15.1.103..
DOI: 10.1200/JCO.1997.15.1.103
Hesketh P.J., Rossi G., Rizzi G., Palmas M., Alyasova A., Bondarenko I. et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340–1346. https://doi.org/10.1093/annonc/mdu110..
DOI: 10.1093/annonc/mdu110
Hesketh P.J., Grunberg S.M., Gralla R.J., Warr D.G., Roila F., de Wit R. et al. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin – The Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–4119. https://doi.org/10.1200/JCO.2003.01.095..
DOI: 10.1200/JCO.2003.01.095
Navari R.M., Gray S.E., Kerr A.C. Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial. J Support Oncol. 2011;9(5):188–195. https://doi.org/10.1016/j.suponc.2011.05.002..
DOI: 10.1016/j.suponc.2011.05.002
Hesketh P.J., Kris M.G., Basch E., Bohlke K., Barbour S.Y., Clark-Snow R.A. et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782–2797. https://doi.org/10.1200/JCO.20.01296..
DOI: 10.1200/JCO.20.01296
Davis M., Hui D., Davies A., Ripamonti C., Capela A., DeFeo G. et al. MASCC antiemetics in advanced cancer updated guideline. Support Care Cancer. 2021;29(12):8097–8107. https://doi.org/10.1007/s00520-021-06437-w..
DOI: 10.1007/s00520-021-06437-w
Siddiqui M.A.A., Scott L.J. Palonosetron. Drugs. 2004;64(10):1125–1132. https://doi.org/10.2165/00003495-200464100-00006..
DOI: 10.2165/00003495-200464100-00006
Rojas C., Raje M., Tsukamoto T., Slusher B.S. Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014;722:26–37. https://doi.org/10.1016/j.ejphar.2013.08.049..
DOI: 10.1016/j.ejphar.2013.08.049
Rojas C., Stathis M., Thomas A.G., Massuda E.B., Alt J., Zhang J. et al. Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor. Anesth Analg. 2008;107(2):469–478. https://doi.org/10.1213/ane.0b013e318172fa74..
DOI: 10.1213/ane.0b013e318172fa74
Boccia R., Grunberg S., Franco-Gonzales E., Rubenstein E., Voisin D. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer. 2013;21(5):1453–1460. https://doi.org/10.1007/s00520-012-1691-5..
DOI: 10.1007/s00520-012-1691-5
Lasseter K.C., Gambale J., Jin B., Bergman A., Constanzer M., Dru J. et al. Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects. J Clin Pharmacol. 2007;47(7):834–840. https://doi.org/10.1177/0091270007301800..
DOI: 10.1177/0091270007301800
Stathis M., Pietra C., Rojas C., Slusher B.S. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689(1–3):25–30. https://doi.org/10.1016/j.ejphar.2012.05.037..
DOI: 10.1016/j.ejphar.2012.05.037
Aapro M., Rugo H., Rossi G., Rizzi G., Borroni M.E., Bondarenko I. et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328–1333. https://doi.org/10.1093/annonc/mdu101..
DOI: 10.1093/annonc/mdu101
Gralla R., Lichinitser M., Van Der Vegt S., Sleeboom H., Mezger J., Peschel C. et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570–1577. https://doi.org/10.1093/annonc/mdg417..
DOI: 10.1093/annonc/mdg417
Zhang L., Lu S., Feng J., Dechaphunkul A., Chang J., Wang D. et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452–458. https://doi.org/10.1093/annonc/mdx698..
DOI: 10.1093/annonc/mdx698
Vardy J., Chiew K.S., Galica J., Pond G.R., Tannock I.F. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94(7):1011–1015. https://doi.org/10.1038/sj.bjc.6603048..
DOI: 10.1038/sj.bjc.6603048
Go S.-I., Koo D.-H., Kim S.T., Song H.-N., Kim R.B., Jang J.-S. et al. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist. 2017;22(11):1354–1361. https://doi.org/10.1634/theoncologist.2017-0129..
DOI: 10.1634/theoncologist.2017-0129
Ito Y., Tsuda T., Minatogawa H., Kano S., Sakamaki K., Ando M. et al. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in HighEmetogenic Chemotherapy. J Clin Oncol. 2018;36(10):1000–1006. https://doi.org/10.1200/JCO.2017.74.4375..
DOI: 10.1200/JCO.2017.74.4375
Shimomura K., Minatogawa H., Mashiko T., Arioka H., Iihara H., Sugawara M. et al. LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial. Ann Oncol. 2021;32:S1339–S1340. https://doi.org/10.1016/j.annonc.2021.08.2144..
DOI: 10.1016/j.annonc.2021.08.2144
Celio L., Bonizzoni E., Bria E. Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapyinduced nausea and vomiting (CINV) caused by high-dose cisplatin. JCO. 2021;39(15_suppl):12093–12093. https://doi.org/10.1200/JCO.2021.39.15_suppl.12093..
DOI: 10.1200/JCO.2021.39.15_suppl.12093
Celio L., Bartsch R., Aapro M. Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapyinduced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study. J Geriatr Oncol. 2023;14(6):101537. https://doi.org/10.1016/j.jgo.2023.101537..
DOI: 10.1016/j.jgo.2023.101537
Celio L., Cortinovis D., Cogoni A.A., Cavanna L., Martelli O., Carnio S. et al. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. BMC Cancer. 2022;22(1):915. https://doi.org/10.1186/s12885-022-10018-3..
DOI: 10.1186/s12885-022-10018-3
Celio L., Cortinovis D., Cogoni A.A., Cavanna L., Martelli O., Carnio S. et al. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study). Sci Rep. 2023;13(1):1257. https://doi.org/10.1038/s41598-023-28464-9..
DOI: 10.1038/s41598-023-28464-9
Arbour K.C., Mezquita L., Long N., Rizvi H., Auclin E., Ni A. et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer. J Clin Oncol. 2018;36(28):2872–2878. https://doi.org/10.1200/JCO.2018.79.0006..
DOI: 10.1200/JCO.2018.79.0006
Pan E.Y., Merl M.Y., Lin K. The impact of corticosteroid use during antiPD1 treatment. J Oncol Pharm Pract. 2020;26(4):814–822. https://doi.org/10.1177/1078155219872786..
DOI: 10.1177/1078155219872786
Spinelli T., Moresino C., Baumann S., Timmer W., Schultz A. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial. Springerplus. 2014;3(1):389. https://doi.org/10.1186/2193-1801-3-389..
DOI: 10.1186/2193-1801-3-389
Gralla R.J., Itri L., Pisko S., Squillante A., Kelsen D., Braun D.J. et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New England Journal of Medicine. 1981;305(16):905–909. https://doi.org/10.1056/nejm198110153051601..
DOI: 10.1056/nejm198110153051601
Marty M., Pouillart P., Scholl S., Droz J.P., Azab M., Brion N. et al. Comparison of the 5-Hydroxytryptamine 3 (Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis. N Engl J Med. 1990;322(12):816–821. https://doi.org/10.1056/NEJM199003223221205..
DOI: 10.1056/NEJM199003223221205
Румянцев А.А., Тюляндина А.С., Федянин М.Ю., Трякин А.А., Покатаев И.А., Румянцев Н.А., Тюляндин С.А. Доступность современной антиэметогенной терапии в России: анализ государственных закупок для оценки клинической практики. Практическая онкология. 2019;20(3):243–252. https://doi.org/10.31917/2003243..
DOI: 10.31917/2003243
Pednekar A., Gupta S., Biswas G., Mv C., Dattatreya P.S., Thomas B. et al. Effectiveness of NEPA, an oral fixed-dose combination of netupitant and palonosetron in the prevention of chemotherapy induce nausea (CIN): A post-hoc analysis. JCO. 2023;41(16_suppl):e24140-e24140. https://doi.org/10.1200/JCO.2023.41.16_suppl.e24140..
DOI: 10.1200/JCO.2023.41.16_suppl.e24140
Yamashita S., Imai S., Momo K., Kashiwagi H., Sato Y., Sugawara M., Takekuma Y. Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database. Biol Pharm Bull. 2021;44(8):1151–1155. https://doi.org/10.1248/bpb.b21-00170..
DOI: 10.1248/bpb.b21-00170
Nakashima K., Murakami H., Yokoyama K., Omori S., Wakuda K., Ono A. et al. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol. 2017;47(9):840–843. https://doi.org/10.1093/jjco/hyx084..
DOI: 10.1093/jjco/hyx084